Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.…
Exagen Inc (XGN) (Q3 2026) Earnings Call Highlights: Record Q3 Revenue, 14th Straight ASP Gain, ...
Exagen (NASDAQ: XGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 216 employees.
The shares were at 3.610 USD on 20 November 2026, down 65.1% over 52 weeks. Its 52-week range is 2.590 USD to 10.82 USD: the price is 66.7% below the high and 39.4% above the low.
Its market capitalisation is 92.10M USD.
Exagen reports return on equity of -114.3%, an operating margin of -19.3% and revenue up 6.8% year over year.
Its debt exceeds its cash by 669.00K USD, a debt-to-equity ratio of 1.47. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.429 USD is 161.2% above the current price. The next earnings report is expected on 16 March 2027.